Unum Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Andrew Fein started Unum Therapeutics with a Buy rating and $18 price target. While most T-cell therapy players are focusing on tackling one or two aspects of the major challenges faced by CAR-T, the differentiating value of Unum resides in its potential to address all aspects especially its unique advantages in targeting solid tumors, where the largest commercial opportunities lie for new entrants in the space, says the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.